Study of 2 Ribociclib Doses in Combination With Aromatase Inhibitors in Women With HR+, HER2- Advanced Breast Cancer

NCT03822468 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

376

Enrollment

INDUSTRY

Sponsor class

Conditions

Breast Cancer

Interventions

DRUG: Ribociclib
DRUG: Anastrozole
DRUG: Letrozole
DRUG: Goserelin

Sponsor

Novartis Pharmaceuticals